Global regulators rise to meet artificial intelligence challenge

For many years, artificial intelligence (AI), in particular machine learning, have been touted as potentially transformational technologies for drug discovery and development.

Now, regulators around the world have come together to try to formalize the integration of these tools into the drug approval process.

The International Coalition of Medicines Regulatory Authorities (ICMRA) has set out recommendations to help regulators address the challenges presented by the use of AI and machine learning.